The Clinical Relevance of Noncriteria Antiphospholipid Antibodies
The Clinical Relevance of Noncriteria Antiphospholipid Antibodies
复制标题
DOI：
10.1055/s-0037-1601328
复制
发表时间：
2018-07-01
影响因子：
5.7
通讯作者：
Sanna, Giovanni
中科院分区：
文献类型：
--
作者：
Bertolaccini, Maria Laura;Sanna, Giovanni
虽然狼疮抗凝剂(LA)、抗心磷脂抗体(ACL)、抗(2)糖蛋白I(抗(2)GPI)抗体在抗磷脂综合征(APS)的研究中是可用和最广泛使用的最佳检测方法，但近年来收集的证据表明，其他抗磷脂抗体(APL)特异性也可能在该综合征中发挥作用。一些自身抗体已被证明与心磷脂以外的磷脂结合，或与GPI的某些区域结合，或与凝血级联的其他蛋白结合，这些自身抗体也被认为与APS有关，其诊断价值和临床应用是当前研究的重点。
While lupus anticoagulant (LA), anticardiolipin antibodies (aCL), anti- (2) glycoprotein I (anti- (2) GPI) antibodies represent the best available and the most widely used tests in the investigation for antiphospholipid syndrome (APS), evidence gathered in recent years indicates that other antiphospholipid antibodies (aPL) specificities may also play a role in the syndrome. Several autoantibodies have been shown to be complexed with phospholipids other than cardiolipin, or to some domains of (2) GPI, or else directed to other proteins of the coagulation cascade, and these have also been proposed to be of relevance to APS, and their diagnostic value and clinical utility are the focus of current research.